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Abstract
Pancreatic cancer is an aggressive solid organ malignancy with a high mortality
rate. There has only been significant improvement in the overall survival until the
last 5–10 years. The current trend toward the neoadjuvant approach of pancreatic
cancer has shown success in tumor response, resection rate, and even overall
survival. Using dedicated pancreatic protocol cross-sectional imaging, one can now
follow the tumor and pancreatic parenchyma interface as well as tumor markers to
predict treatment response. Aggressive combination chemotherapy regimens such
as FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan), approp-
riate patient selection, and multidisciplinary treatment teams have made an impact
in the current management of pancreatic cancer. Surgical intervention is still the
mainstay treatment of pancreatic cancer. The role of routine radiation therapy is
still unknown but may benefit in situations with positive margins.
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1. Introduction
1.1 Incidence and mortality
Pancreatic cancer is the 13th most common malignancy worldwide, which was
diagnosed in approximately 338,000 people in 2012. Pancreatic cancer is a very
aggressive form of malignancy resulting in the seventh leading cause of cancer
deaths worldwide, over 331,000 deaths in 2012 alone. The worldwide incidence of
new pancreatic cancers was 4.9 in 100,000 persons with an associated mortality
rate of approximately 4%. The incidence and deaths of pancreatic cancer is higher
in developed countries, 188,000 and 184,000 persons as compared to less
developed regions, 150,000 and 146,000 persons [1].
Specifically looking at the USA, pancreatic cancer is the eighth most common
type of malignancy and the fourth leading cause of cancer deaths. There are
estimated 55,440 new cases of pancreatic cancer that will be diagnosed in the USA
in 2018 and result in estimated 44,330 deaths. Incidence rate of pancreatic cancer
has increased 1% per year from 2005 to 2014 [2].
Most pancreatic cancers develop from the pancreatic exocrine tissue (94%),
such as invasive ductal adenocarcinoma, while the remaining 6% of tumors stem
from the hormone-producing islet cells, such as insulinomas, gastrinomas, and
other pancreatic neuroendocrine tumors (pNETs). Those pNets will typically occur
in younger patients with a better overall prognosis. The focus of this chapter will be
on invasive pancreatic ductal adenocarcinoma [2].
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The overall pancreatic cancer mortality rate has shown only slight improvement
over the past 35 years. In 1975, pancreatic cancer mortality rate was observed at
3.1%, and in 2000, it increased to 5.2%. The largest incremental improvement in
pancreatic cancer survival has occurred over the past 10 years (2008–2104), with
the all stage 5 year survival between 8 and 8.5% [2–4].
For the small percentage of patients with early-stage localized pancreatic cancer
(10%), the 5-year survival is between 32 and 34.3%. Once regional lymph node
involvement has developed, the 5 year survival decreases to 11.5–12%. Unfortu-
nately, most pancreatic cancer patients (52%) are diagnosed with distant metastatic
disease, and that 5-year survival is only 3% [2, 3].
1.2 Risk factors
At this point in the time, the cause of pancreatic cancer is still unknown. Increa-
sing age is a significant risk factor for developing pancreatic cancer. The median age
of diagnosis of pancreatic cancer in both sexes is at 70 years old. In addition, men
have an increased incidence of developing pancreatic cancer as compared to women,
14.4 vs. 11.2 per 100,000 persons across all race and ethnicity [1–3].
There have been several risk factors to develop pancreatic cancer associated with
race/ethnicity, environmental, dietary, medical, and genetic exposures identified
(Table 1). Race is also another significant risk factor. African-Americans have the
highest incidence (9.9 per 100,000 persons) and mortality (9.4 per 100,000
persons) of pancreatic cancer as compared to non-African-Americans [4]. In
addition, Jews of Ashkenazi heritage also have an increased incidence of pancreatic
cancer. The age standardized incidence rate of pancreatic cancer for Israeli Jews
(7.2 per 100,000 males and 5.7 per 100,000 females) exceeds the incidence of
Israeli non-Jews (4.0 per 100,000 males and 2.9 per 100,000 females) [5].
There are also several hereditary conditions associated with increased risk for
pancreatic cancer (Table 2). While persons with these genetic syndromes are at
increased risk for pancreatic cancer, they only account for 5% of all pancreatic
diagnoses. Familial cases of pancreatic cancer are at increased incidence to develop
secondary primary cancers as compared to non-familial-based cancers. Of those
listed, Peutz-Jeghers and hereditary pancreatitis syndromes have the highest risk of
developing pancreatic cancer [6–12].
Table 1.
Risk factors for developing pancreatic cancer.
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Tobacco use is the most well-established modifiable risk factor for developing
pancreatic cancer and accounts for up to 30% of all pancreatic cancer cases. There is
at least a twofold increase in risk for developing pancreatic cancer in cigarette
smoker than a non-smoker. The risk also increases with an increase in the number
of cigarettes and duration of smoking. It may take up to 20 years after cessation of
cigarette smoking for one’s risk of pancreatic cancer to be equal to take of a non-
smoker [13].
2. Treatment of resectable disease
2.1 Imaging considerations
The current standard in pancreatic cancer staging is by use of a 64-slice
multidetector computed tomography (CT). Specific CT pancreatic protocols can
accurately stage the cancer and assess for resectability. These protocols include both
the use of low-density oral contrast and nonionic iodinated contrast and scanned
30–45 seconds then again 60 seconds after injection to capture both arterial and
Table 2.
Genetic syndromes with increased risk of pancreatic cancer.
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venous phases. The arterial phase will allow for good visualization of the celiac axis,
common hepatic artery, superior mesenteric artery, and gastroduodenal artery. The
venous phase will show enhanced visualization of the portal vein, superior mesen-
teric vein, splenic vein, pancreatic parenchyma, and the liver to assess for meta-
static disease [14, 15].
2.2 Surgical considerations
Only 20% of patients who present with pancreatic cancer can undergo surgical
resection since most patients present with either unresectable or metastatic disease.
The only chance for a curative treatment is with the inclusion of successful surgical
removal of the cancer. To determine the patient’s eligibility for pancreatic resection,
an experienced pancreatic surgeon is required to review the dedicated pancreatic
cross-sectional imaging. The relationship of the tumor to the major intra-abdominal
vessels determines the resectability of the pancreatic cancer. Decisions regarding
diagnostic and management and resectability should involve multidisciplinary con-
sultation at high-volume center, at least 15–20 pancreatic resections per year [14].
In 2006, the National Comprehensive Cancer Network (NCCN) criteria
initially defined pancreatic cancers resectability status into three classifications:
resectable, borderline resectable, and unresectable. Since that time, there have been
several varying definitions of tumor resectability that have evolved over the past
decade. Several international surgical societies such as the American Hepato-
Pancreatico-Biliary Association (AHPBA), Society of Surgical Oncology (SSO),
Society for Surgery of the Alimentary Tract (SSAT), and International Association
of Pancreatology (IAP) have issued consensus statements on the definition and
criteria of resectability and borderline resectable pancreatic cancers as illustrated in
Table 3 [14–16].
For a tumor to be considered resectable, it must not be in contact with the portal
vein (PV) or superior mesenteric vein (SMV) per AHPBA/SSO/SSAT and IAP or
less than 180° of contact with SMV/PV by NCCN criteria. By meeting these criteria,
the surgeon believes there is a high likelihood of removing the cancer without
leaving behind any residual tumor (R0 resection). When pancreatic cancers are
classified as borderline resectable based on the vascular involvement, it means that
there is a higher likelihood of having residual microscopic disease (R1 resection) if
one was to proceed with upfront surgery. Borderline resectable means just that it is
not quite resectable but not completely unresectable either. The criteria are less
than 180° of arterial involvement of the superior mesenteric artery (SMA) or
common hepatic artery (CHA) of celiac axis (CA). It also means there can be
greater than 180° of involvement of SMV or even complete encasement of SMV or
PV but still suitable for resection vascular reconstruction. Unresectable disease has
greater than 180° of arterial involvement of SMA, CHA, or CA or non-
reconstructable vein involvement including the first jejunal branch [14–16].
The best outcomes come from margin negative surgical resection with no
residual microscopic disease (R0). There is current debate at the true definition of
R1 resection as either no microscopic tumor cells at the resection margin or if tumor
cells are less than 1 mm from the resection margin. It has been found that the 5-year
survival rate has been improved in patients with greater than 1 mm of clearance as
compared to those with less than 1 mm. Margins with 0 mm, less than 1 mm, or
greater than 1 mm had 5-year survival rates at 16.3, 12.4, and 27.6%, respectively
[17]. There is no benefit to performing a surgical resection if gross tumor
(R2 resection) will be the result as the prognosis is similar to patients with
non-operative management [18].
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Table 3.
Definitions and criteria of resectable, borderline resectable and unresectable pancreatic cancer.
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Pancreatic surgery should involve high-volume surgeons with the expertise in
pancreatic resection. Decisions regarding the management of pancreatic cancer
patients require a multidisciplinary team. The location of the tumor and extent of
disease will dictate the surgical approaches. Pancreatic head and uncinate tumors
require pancreaticoduodenectomy (Whipple procedure) with reconstruction of the
pancreas, bile duct, and stomach. If possible, the aim is to preserve the pylorus to
limit bile acid reflux and gastric emptying. Tumors that exist in the body and tail of
the pancreas will typically require a left-sided surgical resection, distal pancreatec-
tomy, and splenectomy. Borderline resectable and locally advanced cancers may
also require venous and/or arterial reconstruction at the time of surgical resection of
the pancreatic cancer.
2.3 Chemotherapy
In patients with pancreatic cancer, the overall survival has improved due to
systemic chemotherapy and combination therapies. It is still standard treatment to
perform upfront surgical resection for resectable pancreatic cancer followed by
adjuvant chemotherapy. However, there has been a shift toward upfront
neoadjuvant chemotherapy in order to select out patients with latent metastatic
disease or to downstage borderline and locally advanced cancers.
The ESPAC-1 (European Study Group for Pancreatic Cancer) showed that there
was improvement in overall survival using surgery plus adjuvant 5-fluorouracil
(5-FU) plus folinic acid (FA). This three-tracked trial compared patients treated
with chemotherapy alone, surgical resection alone, or chemotherapy plus radiation
therapy. The highest 5-year survival was seen in the chemotherapy arm 21% as
compared to surgery alone 8% and chemoradiation 11%. This revealed the only
significant survival benefit was with adjuvant chemotherapy [19].
The Charite Onkologie study (CONKO-001) from 2007 compared adjuvant
gemcitabine therapy to observation in patients undergoing surgical resection of
pancreatic cancer. In the treatment arm, patients received 6 cycles of adjuvant
gemcitabine. Patients treated with adjuvant gemcitabine vs. surgery alone had
statistically significant increased median overall survival of 22.8 months and 5-year
survival of 21% compared to 20.2 months and 5-year survival of 9%. Gemcitabine
also significantly delayed the development of recurrent disease as compared to
observation alone [20].
The ESPAC-3 was a large randomized controlled trial which compared
adjuvant 5-FU plus leucovorin or gemcitabine in patients who underwent RO or
R1 resection of pancreatic cancer. This was initially a three-arm study comparing
5-FU plus leucovorin, gemcitabine, and observation; however, once the results of
the ESPAC-1 were available, the observation arm was closed. Results of ESPAC-1,
ESPAC-1 plus, and ESPAC-3 in subset analysis of 5-FU/FA vs. observation
confirmed that adjuvant 5-FU/FA had superior overall survival as compared to
observation after surgical resection. The 5 year survival for 5-FU/FA was 24%
compared to observation which was 14% [21].
ESPAC-3 has enrolled 1088 patients and they were followed for over 6.5 years.
Median survival for gemcitabine arm was 23.6 months while 5FU/leucovorin arm
was 23 months [22]. This had shown that adjuvant gemcitabine had similar survival
but less toxicity as compared to 5FU. At this point, there were now two different
adjuvant treatment options for resected pancreatic cancer.
Van Hoof et al. (2013) performed a phase III trial in which metastatic pancreatic
cancer patients were randomized to treatment with either nab-paclitaxel (125 mg
per square meter of body surface area) plus gemcitabine (1000 mg per square
meter) on days 1, 8, and 15 every 4 weeks or gemcitabine monotherapy
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(1000 mg per square meter) weekly for 7 of 8 weeks and then on days 1, 8, and 15
every 4 weeks. The overall survival in the nab-paclitaxel-gemcitabine was
8.5 months as compared to gemcitabine alone with 6.7 months (p > 0.001). This
doublet therapy did result in higher rates of myelosuppression and peripheral neu-
ropathy than gemcitabine alone [23]. While this study was based on patients with
metastatic disease, it advanced the adjuvant combined chemotherapy regimen in
resected pancreatic cancer.
The ESPAC-4 went on to compare adjuvant gemcitabine and capecitabine with
gemcitabine monotherapy in patients with resected pancreatic cancer. Capecitabine
is an orally active fluoropyrimidine carbamate which can provide prolonged fluo-
rouracil exposure at lower peak concentrations. The 5-year overall survival with
gemcitabine and capecitabine compared to gemcitabine alone was 29% vs. 16%
[24]. The new standard of care quickly adopted doublet therapy as the new
standard of care.
The use of adjuvant FOLFIRINOX [fluorouracil (5-FU), leucovorin, irinotecan,
oxaliplatin] has been extrapolated from the treatment of pancreatic cancer in the
metastatic setting. In the ACCORD-11 trial, FOLFIRINOX was found to have a
superior survival advantage over gemcitabine in metastatic pancreatic patients with
median overall survival of 11.1 months vs. 6.8 months [25]. This study ultimately
launched FOLFIRINOX into new treatment paradigms in the adjuvant and
neoadjuvant settings.
The phase III PRODIGE 24/CCTG PA.6 trial compared a modified FOLFIRINOX
regimen against single-agent gemcitabine therapy, as the results of the ESPAC-4
were not known at study design. This study used a modified FOLFIRINOX regimen:
oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, and irinotecan 180 mg/m2 (dose
reduced to 150 mg/m2 after patient 162) on day 1 and continuous fluorouracil
infusion 2.4 gm/m2 over 46 hours. This regimen was repeated every 2 weeks for
12 cycles. The gemcitabine regimen was 1000 mg/m2 once per 3 of 4 weeks for
6 cycles [26]. The response rate was 31.18% in the mFOLFIRINOX group and 11.3%
in the gemcitabine group. The disease-free survival (DFS) and overall survival (OS)
in the mFOLFIRINOX arm were 21.6 and 54.4 months, while the gemcitabine arm
were 17.7 and 35.0 months repetitively. Grade 3 or 4 adverse events (neutropenia,
diarrhea, neuropathy) were significantly higher in the FOLFIRINOX treatment arm
than the gemcitabine arm [26].
mFOLFIRINOX has been the largest advancement in overall survival for
resected pancreatic cancer patients, which more than doubled the previous median
overall survival.
2.4 Radiation therapy
There are mixed opinions regarding the routine use of radiation therapy in
pancreatic cancer. The ESPAC-1 did not reveal any significant survival benefit with
chemoradiation [19]. A meta-analysis of five randomized controlled trials using
adjuvant chemoradiation in patients who underwent curation resection was
performed to assess the survival benefit. It appeared that adjuvant chemoradiation
had benefitted the subset of patients with a positive margin status; however, it was
not statistically significant [27].
The RTOG study looks to determine if the addition of gemcitabine to adjuvant
fluorouracil chemoradiation improved survival as compared with fluorouracil.
Patients were given either fluorouracil (continuous infusion 250 mg/m2 per day) or
30 minutes infusion of gemcitabine (1000 mg/m2 once a week) for 3 weeks prior to
fluorouracil chemoradiation and for 12 weeks following chemoradiation. The
median survival for the gemcitabine group was 20.5 months, while the median
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survival for the fluorouracil group was 16.9 months. There appeared to be a survival
benefit, but it was not statistically significant [28].
The LAP07 randomized clinical trial aimed to assess if chemoradiation would
improve overall survival after 4 months of gemcitabine and to assess erlotinib’s
effect on survival as well as in patients with locally advanced pancreatic cancer.
There was no difference in overall survival between the chemotherapy alone vs. the
addition of chemoradiation, 16.5 months vs. 15.2 months [29].
While variations may occur at different institutions, a common approach for
resectable pancreatic cancer would include the surgical resection of the cancer
followed by adjuvant chemotherapy. The use of radiation may be used in the
adjuvant setting for positive margins following chemotherapy after proving no
metastatic disease developed.
3. Treatment of borderline and locally advanced disease
3.1 Neoadjuvant therapy
For patients that present with borderline resectable and locally advanced
pancreatic cancer, neoadjuvant chemotherapy with or without chemoradiation
allows for systemic control and may improve the likelihood of a R0 resection. The
initial rationale for upfront therapies is to potentially downstage tumors to become
resectable with a higher R0 resection rate and to allow potential latent metastatic
disease to declare itself. In addition, the use of neoadjuvant chemoradiation may be
used to “sterilize” the tumor margins near vessel involvement. This allows for
selection of the most appropriate patients who have the highest likelihood of long-
term survival.
Based on the ACCORD-11 trial showing superior response to FOLFIRINOX, this
regimen has now been used effectively in the neoadjuvant setting for borderline and
locally advanced pancreatic cancers. Several series have been published showing
institutional success. The Massachusetts General Hospital reported that patients
treated with mFOLFIRINOX have significantly smaller tumors and lower rates of
lymphovascular invasion and perineural invasion. The R0 resection was 92% [30].
Similar reports from the Ohio State University were also noted. They were also
able to convert locally advanced and unresectable pancreatic cancers to resectable
in 51% of patients who underwent neoadjuvant mFOLFIRINOX with R0 resection
of 86% [31].
While patients are undergoing neoadjuvant chemotherapy, serial imaging with
pancreatic protocol CT is used to observe for treatment response. In those patients
that develop metastatic disease or progression to unresectable disease while under-
going neoadjuvant, their poor biology of disease had declared itself, and they were
spared the major morbidity of a surgical resection. For those demonstrating stable
or treatment response, the radiologic imaging can be used to predict treatment
response. The appearance of the tumor and pancreatic parenchyma interface that
becomes more distinct indicates a cytotoxic response which ultimately translates to
pathologic response. The ideal response is for the tumor to pull away from the
vessels and no longer see haziness around the vessels, which may indicate an
infiltrative process. Another prognostic marker of treatment response is normaliza-
tion of CA 19–9 during neoadjuvant therapy [32].
A pathologic complete response (pCR) can be found in approximately 10% of
patients treated in the neoadjuvant approach with FOLFIRINOX and
chemoradiation. This is also an independent prognostic risk factor for improved
overall and disease-free survival [33]. Additionally, small tumor size, negative
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margins, and negative lymph node metastasis are favorable prognostic indicators
for improved overall and disease-free survival.
The consensus for treatment of borderline resectable pancreatic cancer favors
the neoadjuvant approach; however, it may vary per institution. After a multidis-
ciplinary review at our hospital, the typical functional patient would undergo
neoadjuvant chemotherapy (FOLFIRINOX) for 3–4 cycles followed by restaging
with CT and CA 19–9. If stable or responding disease, then the patient would
continue additional 3–4 cycles of FOLFIRINOX. The patient would again be
restaged with CT and CA 19–9. Barring no metastatic disease developed and there
was treatment response, the patient would then undergo surgical intervention.
However, if the surgical margins were still threatened and there was concern for R1
resection, then the patient may undergo chemoradiation to “sterilize” the margins.
Approximately 4–6 weeks after chemoradiation, the patient would ultimately
undergo surgical resection.
4. Unresectable pancreatic cancer
Unresectable pancreatic cancer means that the tumor cannot safely be removed
due to vascular involvement or metastatic disease. Patients may undergo aggressive
chemotherapy with FOLFIRINOX, and a few may be able to convert to a resectable
cancer. It is of utmost importance for early palliative care interventions in these
patients. For those with biliary obstruction, the use of endoscopic biliary stents and
percutaneous biliary drains may provide relief from the jaundice. If the tumor is
found to be unresectable in the operating room, then palliative hepaticojejunostomy
may be performed. Gastric outlet obstruction may also be relieved with endoscop-
ically placed luminal stents. Additionally, surgical bypass may be performed in
laparoscopic or open fashion with a gastrojejunostomy.
Pain can also become quite debilitating in patients with locally advanced
unresectable pancreatic cancer. Celiac plexus neurolysis can be performed at the
time of surgical exploration, or it may be performed by endoscopic or percutaneous
routes.
Irreversible electroporation (IRE) is a nonthermal ablative modality which relies
on high voltage (maximum 3,000 volts) small microsecond pulse lengths. This is a
novel option typically used in locally advanced pancreatic adenocarcinoma of the
head or neck that is not amendable to resection. Some institutions are now using
IRE to assist with the resection of locally advanced tumors, but this is not standard
at this time. The procedure may be performed open or percutaneously. Patients will
typical undergo several months of neoadjuvant chemotherapy to not miss occult
metastatic disease prior to IRE. IRE can improve progression-free survival from 6 to
14 months and overall survival from 23 to 20 months [34].
5. Clinical trials
There are several active clinical trials investigating additional treatment options
for pancreatic cancer. Several phase II trials are looking at the use of targeted agents
in addition to systemic chemotherapy. One study is evaluating the safety of
niraparib, PARP [poly (ADP-ribose) polymerase] inhibitor, in advanced pancreatic
cancer patients [35]. Another clinical trial at the Massachusetts General Hospital is
using the checkpoint inhibitor, nivolumab, as programed death-1 (PD-1) inhibition
in combination with losartan, FOLFIRINOX, stereotactic body radiation therapy
(SBRT), and surgery in advanced pancreatic cancer. This is a three-armed study:
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Arm 1 with FOLFIRINOX, SBRT, and then surgery; Arm 2 with FOLFIRINOX plus
losartan, SBRT plus losartan, and then surgery; and Arm 3 with FOLFIRINOX plus
losartan, SBRT plus nivolumab and losartan, and then surgery [36].
Reviewing the past studies on chemoradiation, one must keep in mind these
studies were using monotherapy chemotherapy and conventional fractionated
radiation therapy. There are now several clinical trials assessing the role of radiation
therapy, specifically SBRT in the setting of FOLFIRINOX. SBRT utilizes high doses
of ablative radiotherapy in typically 1–5 fractions.
The ALLIANCE A021501 is a randomized controlled trial using modified
FOLFIRINOX regimen (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin
400 mg/m2, and infusional 5-fluorouracil 2400 mg/m2 over 2 days for 4 cycles) in
borderline resectable pancreatic head adenocarcinomas. Arm 1 is delivering this
regimen for 8 cycles, while Arm 2 is receiving 7 cycles followed by SBRT
(33–40 Gy in 5 fractions). The patient then undergoes pancreaticoduodenectomy
followed 4 cycles of adjuvant-modified FOLFOX6 (oxaliplatin 85 mg/m2,
leucovorin 400 mg/m2, bolus 5-fluorouracil 400 mg/m2, and infusional 5-fluoro-
uracil 2400 mg/m2 over 2 days for 4 cycles). The main aim of this study is to assess
18-month overall survival, R0 resection, and event-free survival [37].
Another randomized controlled trial by the Pancreatic Cancer Radiotherapy
Study Group (PanCRS) is assessing the progression-free survival between
mFOLFIRINOX alone vs. mFOLFIRINOX and SBRT in locally advanced
unresectable pancreatic cancer [38].
Also, a novel class of drug, cancer stemness inhibitors, is being investigated as a
potential new treatment for pancreatic cancer. Napabucasin is an oral small mole-
cule that blocks stem cell activity by targeting the signal transducer and activator of
transcription 3 pathway. This pathway is believed to be an important pathway in
the propagation of stem-cell-mediated cancer cells [39].
6. Conclusion
While pancreatic cancer is still an aggressive malignancy which is often lethal,
there have been significant improvements in the systemic chemotherapy which has
improved patients’ overall survival. In addition, the radiographic quality has
improved thus we are better able to appropriately stage patients for resectability
from the onset. Future research in the use of targeted and immunotherapy and the
promise of SBRT may control to improve the outcomes of pancreatic cancer
patients. With the use of multidisciplinary treatment teams, aggressive combination
chemotherapies and surgical resections, there is hope for the patients with pancre-
atic cancer.
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